Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Guardian Pharmacy Services, Inc. (NASDAQ:GRDN), a $1.4 billion market cap healthcare company trading above its InvestingPro Fair Value, witnessed a significant stock sale by Bindley Capital Partners (WA:CPAP) I, LLC, a ten percent owner, according to a recent SEC filing. On May 27 and 28, Bindley Capital Partners sold a total of 4,159,359 shares of Guardian’s Class A Common Stock at a price of $20.16 per share, amounting to approximately $83.87 million.
Following these transactions, Bindley Capital Partners now holds 1,939,817 shares of Guardian Pharmacy Services. The sales were conducted under an underwriting agreement involving Raymond (NSE:RYMD) James & Associates, Inc., acting as the representative for the underwriters.
In other recent news, Guardian Pharmacy Services reported a notable 20% increase in revenue for the first quarter of 2025, reaching $329.3 million. The company also announced a modest rise in earnings per share (EPS) to $0.15. Guardian Pharmacy’s optimistic outlook for the year includes expectations for full-year revenue to be in the upper half of their projected range of $1.33 billion to $1.35 billion. Additionally, Guardian Pharmacy Services has expanded its operations with the acquisition of Senior Care Pharmacy in Wichita, Kansas, enhancing its service capabilities in the state. This acquisition aligns with Guardian’s strategy of growth through acquisitions and organic expansion. Furthermore, Guardian Pharmacy Services announced a proposed public offering of 7.5 million shares of Class A common stock, with Raymond James leading the offering. The proceeds from this offering will fund a stock repurchase agreement, ensuring the total number of outstanding shares remains unchanged. The company has also entered into stock purchase agreements to repurchase up to 1,457,365 shares of its Class A common stock in a private transaction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.